HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF METHOCARBAMOL ENANTIOMERS IN BIOLOGICAL-FLUIDS

被引:22
作者
ALESSISEVERINI, S [1 ]
COUTTS, RT [1 ]
JAMALI, F [1 ]
PASUTTO, FM [1 ]
机构
[1] UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI,EDMONTON T6G 2N8,ALBERTA,CANADA
来源
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS | 1992年 / 582卷 / 1-2期
关键词
D O I
10.1016/0378-4347(92)80316-I
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Methocarbamol enantiomers in rat and human plasma were quantified using a stereospecific high-performance liquid chromatographic method. Racemic methocarbamol and internal standard, (R)-(-)-flecainide, were isolated from plasma by a single-step extraction with ethyl acetate. After derivatization with the enantiomerically pure reagent (S)-(+)-1-(1-naphthyl)ethyl isocyanate, methocarbamol diastereomers and the (R)-flecainide derivative were separated on a normal-phase silica column with a mobile phase consisting of hexane-isopropanol (95:5, v/v) at a flow-rate of 1.6 ml/min. Ultraviolet detection was carried out at a wavelength of 280 nm. The resolution factor between the diastereomers was 2.1 (alpha = 1.24). An excellent linearity was observed between the methocarbamol diastereomers/internal standard derivative peak-area ratios and plasma concentrations, and the intra- and inter-day coefficients of variation were always < 9.8%. The lowest quantifiable concentration was 0.5 mug/ml for each enantiomer (coefficients of variation of 9.8 and 8.8% for (S)- and (R)-methocarbamol, respectively), while the limit of detection (signal-to-noise ratio 3:1) was approximately 10 ng/ml. The assay was used to study the pharmacokinetics of methocarbamol enantiomers in a rat following intravenous administration of a 120 mg/kg dose of racemic methocarbamol and to evaluate plasma and urine concentrations in a human volunteer after oral administration of a 1000-mg dose of the racemate. The method is suitable for stereoselective pharmacokinetic studies in humans as well as in animal models.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 10 条
[1]  
ALESSISEVERINI A, 1991, PHARMACEUT RES, V8, pS30
[2]   METABOLISM OF METHOCARBAMOL IN RAT, DOG, AND HUMAN [J].
BRUCE, RB ;
TURNBULL, LB ;
NEWMAN, JH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (01) :104-&
[3]  
CAMPBELL AD, 1961, J PHARMACOL EXP THER, V131, P18
[4]  
CARPENTER E B, 1958, South Med J, V51, P627, DOI 10.1097/00007611-195805000-00013
[5]   COMPARATIVE PHARMACOKINETICS OF CHLORPHENESIN CARBAMATE AND METHOCARBAMOL IN MAN [J].
FORIST, AA ;
JUDY, RW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (11) :1686-&
[6]  
HUF EG, 1959, P SOC EXP BIOL MED, V102, P276
[7]   ENANTIOSELECTIVE ASPECTS OF DRUG-ACTION AND DISPOSITION - THERAPEUTIC PITFALLS [J].
JAMALI, F ;
MEHVAR, R ;
PASUTTO, FM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (09) :695-715
[8]  
MUIR WW, 1984, AM J VET RES, V45, P2256
[9]   PHARMACOKINETICS AND BIOAVAILABILITY OF METHOCARBAMOL IN RATS [J].
OBACH, R ;
PRUNONOSA, J ;
MENARGUES, A ;
NOMEN, M ;
VALLES, J .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1988, 9 (05) :501-511
[10]   PHARMACOKINETICS AND PROTEIN-BINDING OF METHOCARBAMOL IN RENAL-INSUFFICIENCY AND NORMALS [J].
SICA, DA ;
COMSTOCK, TJ ;
DAVIS, J ;
MANNING, L ;
POWELL, R ;
MELIKIAN, A ;
WRIGHT, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (02) :193-194